APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Multiple Sclerosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025183 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multiple Sclerosis Drugs include ACORDA, Biogen, Mallinckrodt, Bayer, Merck KGaA, Novartis, Sanofi and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multiple Sclerosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Sclerosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Sclerosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multiple Sclerosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multiple Sclerosis Drugs Segment by Company

ACORDA

Biogen

Mallinckrodt

Bayer

Merck KGaA

Novartis

Sanofi

Teva

Multiple Sclerosis Drugs Segment by Type

Injectable Medications

Oral Medications

Others

Multiple Sclerosis Drugs Segment by Application

Adults

Children

Multiple Sclerosis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multiple Sclerosis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multiple Sclerosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Multiple Sclerosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Multiple Sclerosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Multiple Sclerosis Drugs Industry Trends Table 2. Multiple Sclerosis Drugs Industry Drivers Table 3. Multiple Sclerosis Drugs Industry Opportunities and Challenges Table 4. Multiple Sclerosis Drugs Industry Restraints Table 5. Global Multiple Sclerosis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Multiple Sclerosis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Multiple Sclerosis Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers Table 9. Global Multiple Sclerosis Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Multiple Sclerosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Multiple Sclerosis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Multiple Sclerosis Drugs Manufacturers, Product Type & Application Table 13. Global Multiple Sclerosis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Multiple Sclerosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injectable Medications Table 17. Major Manufacturers of Oral Medications Table 18. Major Manufacturers of Others Table 19. Global Multiple Sclerosis Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Multiple Sclerosis Drugs Sales by Type (2021-2026) & (W Units) Table 21. Global Multiple Sclerosis Drugs Sales by Type (2027-2032) & (W Units) Table 22. Global Multiple Sclerosis Drugs Sales Market Share by Type (2021-2026) Table 23. Global Multiple Sclerosis Drugs Sales Market Share by Type (2027-2032) Table 24. Global Multiple Sclerosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Multiple Sclerosis Drugs Revenue by Type (2021-2026) & (W Units) Table 26. Global Multiple Sclerosis Drugs Revenue by Type (2027-2032) & (W Units) Table 27. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Adults Table 30. Major Manufacturers of Children Table 31. Global Multiple Sclerosis Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Multiple Sclerosis Drugs Sales by Application (2021-2026) & (W Units) Table 33. Global Multiple Sclerosis Drugs Sales by Application (2027-2032) & (W Units) Table 34. Global Multiple Sclerosis Drugs Sales Market Share by Application (2021-2026) Table 35. Global Multiple Sclerosis Drugs Sales Market Share by Application (2027-2032) Table 36. Global Multiple Sclerosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Multiple Sclerosis Drugs Revenue by Application (2021-2026) & (W Units) Table 38. Global Multiple Sclerosis Drugs Revenue by Application (2027-2032) & (W Units) Table 39. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Multiple Sclerosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Multiple Sclerosis Drugs Sales by Region (2021-2026) & (W Units) Table 43. Global Multiple Sclerosis Drugs Sales Market Share by Region (2021-2026) Table 44. Global Multiple Sclerosis Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 45. Global Multiple Sclerosis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 47. North America Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 48. North America Multiple Sclerosis Drugs Sales by Country (2027-2032) & (W Units) Table 49. Europe Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. Europe Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 51. Europe Multiple Sclerosis Drugs Sales by Country (2027-2032) & (W Units) Table 52. Asia Pacific Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Asia Pacific Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 54. Asia Pacific Multiple Sclerosis Drugs Sales by Country (2027-2032) & (W Units) Table 55. South America, Middle East and Africa Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. South America, Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2021-2026) & (W Units) Table 57. South America, Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2027-2032) & (W Units) Table 58. Global Multiple Sclerosis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Multiple Sclerosis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Multiple Sclerosis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2027-2032) Table 63. ACORDA Company Information Table 64. ACORDA Business Overview Table 65. ACORDA Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. ACORDA Multiple Sclerosis Drugs Product Portfolio Table 67. ACORDA Recent Development Table 68. Biogen Company Information Table 69. Biogen Business Overview Table 70. Biogen Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Biogen Multiple Sclerosis Drugs Product Portfolio Table 72. Biogen Recent Development Table 73. Mallinckrodt Company Information Table 74. Mallinckrodt Business Overview Table 75. Mallinckrodt Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Mallinckrodt Multiple Sclerosis Drugs Product Portfolio Table 77. Mallinckrodt Recent Development Table 78. Bayer Company Information Table 79. Bayer Business Overview Table 80. Bayer Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Bayer Multiple Sclerosis Drugs Product Portfolio Table 82. Bayer Recent Development Table 83. Merck KGaA Company Information Table 84. Merck KGaA Business Overview Table 85. Merck KGaA Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Merck KGaA Multiple Sclerosis Drugs Product Portfolio Table 87. Merck KGaA Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Novartis Multiple Sclerosis Drugs Product Portfolio Table 92. Novartis Recent Development Table 93. Sanofi Company Information Table 94. Sanofi Business Overview Table 95. Sanofi Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Sanofi Multiple Sclerosis Drugs Product Portfolio Table 97. Sanofi Recent Development Table 98. Teva Company Information Table 99. Teva Business Overview Table 100. Teva Multiple Sclerosis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Teva Multiple Sclerosis Drugs Product Portfolio Table 102. Teva Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Multiple Sclerosis Drugs Distributors List Table 106. Multiple Sclerosis Drugs Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Multiple Sclerosis Drugs Product Image Figure 2. Global Multiple Sclerosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis Drugs Sales (2021-2032) & (W Units) Figure 5. Global Multiple Sclerosis Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Multiple Sclerosis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injectable Medications Image Figure 9. Oral Medications Image Figure 10. Others Image Figure 11. Global Multiple Sclerosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Multiple Sclerosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Multiple Sclerosis Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Multiple Sclerosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Multiple Sclerosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2021-2032) Figure 17. Adults Image Figure 18. Children Image Figure 19. Global Multiple Sclerosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Multiple Sclerosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Multiple Sclerosis Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Multiple Sclerosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Multiple Sclerosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 26. North America Multiple Sclerosis Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 28. Canada Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Mexico Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Europe Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 33. France Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 34. U.K. Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Italy Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Netherlands Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Asia Pacific Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Country (2021-2032) Figure 39. China Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Japan Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. South Korea Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Southeast Asia Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. India Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Australia Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South America, Middle East and Africa Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South America, Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South Africa Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Saudi Arabia Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Turkey Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Argentina Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. UAE Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Egypt Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Chile Multiple Sclerosis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Global Multiple Sclerosis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Multiple Sclerosis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Multiple Sclerosis Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Multiple Sclerosis Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Multiple Sclerosis Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Multiple Sclerosis Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Multiple Sclerosis Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Multiple Sclerosis Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Injectable Medications
  • Oral Medications
  • Others
Applications
  • Adults
  • Children
Companies covered
  • ACORDA
  • Biogen
  • Mallinckrodt
  • Bayer
  • Merck KGaA
  • Novartis
  • Sanofi
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multiple Sclerosis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multiple Sclerosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Multiple Sclerosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Multiple Sclerosis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Multiple Sclerosis Drugs Market Dynamics
  1. 2.1 Multiple Sclerosis Drugs Industry Trends
  2. 2.2 Multiple Sclerosis Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis Drugs Industry Restraints
3 Multiple Sclerosis Drugs Market by Manufacturers
  1. 3.1 Global Multiple Sclerosis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Multiple Sclerosis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Multiple Sclerosis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Multiple Sclerosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multiple Sclerosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Multiple Sclerosis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Multiple Sclerosis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multiple Sclerosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multiple Sclerosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multiple Sclerosis Drugs Tier 1, Tier 2, and Tier 3
4 Multiple Sclerosis Drugs Market by Type
  1. 4.1 Multiple Sclerosis Drugs Type Introduction
  2. 4.1.1 Injectable Medications
  3. 4.1.2 Oral Medications
  4. 4.1.3 Others
  5. 4.2 Global Multiple Sclerosis Drugs Sales by Type
  6. 4.2.1 Global Multiple Sclerosis Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multiple Sclerosis Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Multiple Sclerosis Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Multiple Sclerosis Drugs Revenue by Type
  10. 4.3.1 Global Multiple Sclerosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Multiple Sclerosis Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2021-2032)
5 Multiple Sclerosis Drugs Market by Application
  1. 5.1 Multiple Sclerosis Drugs Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Multiple Sclerosis Drugs Sales by Application
  5. 5.2.1 Global Multiple Sclerosis Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multiple Sclerosis Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Multiple Sclerosis Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Multiple Sclerosis Drugs Revenue by Application
  9. 5.3.1 Global Multiple Sclerosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multiple Sclerosis Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2021-2032)
6 Global Multiple Sclerosis Drugs Sales by Region
  1. 6.1 Global Multiple Sclerosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Sclerosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Multiple Sclerosis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Multiple Sclerosis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Multiple Sclerosis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Multiple Sclerosis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Multiple Sclerosis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Multiple Sclerosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Multiple Sclerosis Drugs Revenue by Region
  1. 7.1 Global Multiple Sclerosis Drugs Revenue by Region
  2. 7.1.1 Global Multiple Sclerosis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Multiple Sclerosis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Multiple Sclerosis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Multiple Sclerosis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Multiple Sclerosis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Multiple Sclerosis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Multiple Sclerosis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Multiple Sclerosis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Multiple Sclerosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ACORDA
  2. 8.1.1 ACORDA Company Information
  3. 8.1.2 ACORDA Business Overview
  4. 8.1.3 ACORDA Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ACORDA Multiple Sclerosis Drugs Product Portfolio
  6. 8.1.5 ACORDA Recent Developments
  7. 8.2 Biogen
  8. 8.2.1 Biogen Company Information
  9. 8.2.2 Biogen Business Overview
  10. 8.2.3 Biogen Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biogen Multiple Sclerosis Drugs Product Portfolio
  12. 8.2.5 Biogen Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Multiple Sclerosis Drugs Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 Merck KGaA
  26. 8.5.1 Merck KGaA Company Information
  27. 8.5.2 Merck KGaA Business Overview
  28. 8.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio
  30. 8.5.5 Merck KGaA Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Multiple Sclerosis Drugs Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Multiple Sclerosis Drugs Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Multiple Sclerosis Drugs Product Portfolio
  48. 8.8.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multiple Sclerosis Drugs Value Chain Analysis
  2. 9.1.1 Multiple Sclerosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multiple Sclerosis Drugs Production Mode & Process
  6. 9.2 Multiple Sclerosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multiple Sclerosis Drugs Distributors
  9. 9.2.3 Multiple Sclerosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst